An Open-Label, Multicenter, Multiple-Dose Pharmacokinetic, Safety And Efficacy Trial Of Maraviroc In Combination With Optimized Background Therapy For The Treatment Of Antiretroviral-Experienced CCR5-Tropic HIV-1 Infected Children 2 - <18 Years Of Age

Trial Profile

An Open-Label, Multicenter, Multiple-Dose Pharmacokinetic, Safety And Efficacy Trial Of Maraviroc In Combination With Optimized Background Therapy For The Treatment Of Antiretroviral-Experienced CCR5-Tropic HIV-1 Infected Children 2 - <18 Years Of Age

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Nov 2017

At a glance

  • Drugs Maraviroc (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors ViiV Healthcare
  • Most Recent Events

    • 07 Oct 2017 Results published in the Pediatric Infectious Disease Journal
    • 14 Aug 2017 Planned End Date changed from 1 Jul 2019 to 29 Nov 2018.
    • 26 Jul 2017 Results (n=97) assessing pharmacokinetics and dosing recommendations, presented at the 9th International AIDS Society Conference on HIV Science.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top